Agendia is a precision oncology company committed to improving clinical outcomes and informing the journey for patients with early stage breast cancer. Through its state-of-the-art laboratory, the company currently offers two commercially-available genomic profiling tests. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. By developing evidence-based novel genomic tests, Agendia aims to support the evolving clinical needs of breast cancer patients and their physicians.
Facebook
Twitter
LinkedIn
Forward